SAB Biotherapeutics (SABSW) Payables (2020 - 2025)
Historic Payables for SAB Biotherapeutics (SABSW) over the last 6 years, with Q3 2025 value amounting to $6.9 million.
- SAB Biotherapeutics' Payables fell 43.22% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 43.22%. This contributed to the annual value of $5.7 million for FY2024, which is 2575.41% down from last year.
- Per SAB Biotherapeutics' latest filing, its Payables stood at $6.9 million for Q3 2025, which was down 43.22% from $7.1 million recorded in Q2 2025.
- SAB Biotherapeutics' 5-year Payables high stood at $14.3 million for Q4 2021, and its period low was $5.7 million during Q2 2024.
- In the last 5 years, SAB Biotherapeutics' Payables had a median value of $7.0 million in 2024 and averaged $8.2 million.
- Per our database at Business Quant, SAB Biotherapeutics' Payables skyrocketed by 7610.76% in 2021 and then crashed by 4307.75% in 2023.
- Over the past 5 years, SAB Biotherapeutics' Payables (Quarter) stood at $14.3 million in 2021, then dropped by 24.99% to $10.7 million in 2022, then fell by 27.57% to $7.7 million in 2023, then decreased by 25.75% to $5.7 million in 2024, then increased by 19.15% to $6.9 million in 2025.
- Its last three reported values are $6.9 million in Q3 2025, $7.1 million for Q2 2025, and $6.2 million during Q1 2025.